Market Overview

Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

In a report published Friday, Credit Suisse analyst Jason Kantor maintained a Neutral rating on Ariad Pharmaceuticals (NASDAQ: ARIA) and raised the price target from $5.00 to $8.00 on higher Iclusig estimates and possible acquisition.

Kantor noted that a survey from 50 doctors suggests that Ariad's Iclusig remains the “essential drug” for chronic myeloid leukemia patients with T3151 or other mutations. The analyst commented that doctors have a heightened awareness of safety concerns. Credit Suisse added that 38% of doctors sampled report observing at least one adverse event listed in warnings in Iclusig prescribing information.

Ariad Pharmaceuticals closed at $7.17 on Thursday. Shares were up 5.6% in pre-market trading and have traded as high as $8.29, up 15.62% on Friday.

Latest Ratings for ARIA

Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Price Target Analyst Ratings


Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters